Intas Pharma has agreed to buy the Udenyca brand through its US specialty division, Accord BioPharma, for up to $558.4 million (nearly ₹4,800 crore), according to a press release.
Udenyca is the brand name for medication pegfilgrastim-cbqv, a bone marrow stimulant used to treat low white blood-cell counts in patients who take cancer medications.
Denne historien er fra January 08, 2025-utgaven av Mint Hyderabad.
Start din 7-dagers gratis prøveperiode på Magzter GOLD for å få tilgang til tusenvis av utvalgte premiumhistorier og 9000+ magasiner og aviser.
Allerede abonnent ? Logg på
Denne historien er fra January 08, 2025-utgaven av Mint Hyderabad.
Start din 7-dagers gratis prøveperiode på Magzter GOLD for å få tilgang til tusenvis av utvalgte premiumhistorier og 9000+ magasiner og aviser.
Allerede abonnent? Logg på
How Bhansali Elevates the First Encounter
Love at first sight is an emotionally dense moment, predicting the intensity of the journey that the lovers will chart
The Treasures of Nimrud Pieced Together Again
The UNESCO-listed archaeological site was ravaged by Islamic State fighters
From arrack to wine, a bar crawl across Sri Lanka
Cocktail bars in the island nation are drawing on local traditions and flavours to give a heady twist to familiar spirits
Only human-centred AI can charm humans to adopt it
The AI industry could learn from carmakers how to focus on the consumer and modify perceptions
How Emerging Economies Could Prosper in a Protectionist World
As manufacturing export success gets harder, they should focus on service exports. These are unlikely to face big trade barriers
The Asian Dream is waking up to realities of middle-class life
Asians are realizing that staying middle-class is not guaranteed
Fix India's bond market to lift economic growth
As India's economy slows, we should revive public-private partnerships to attract private investment. But, for debt funding, we'll need to reform and invigorate our market for bonds
Lessons from the 75-year-old National Sample Survey
Its impressive history tells us much about innovation, autonomy and state-level data collection
We should let clarity prevail over nonsense: Here's a handy guide
We must use simple language, empathize with people, not take ourselves too seriously and be kind
Clear Goals and Discipline: How Small Investors Can Build Lasting Wealth
There is no one-size-fits-all, the answer will depend on your needs, personal preferences
